MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1634/theoncologist.2012-0251

Медицинская библиотека · The oncologist · 2013

Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Kalpadakis Christina, Pangalis Gerassimos A, Angelopoulou Maria K, Sachanas Sotirios, Kontopidou Flora N, Yiakoumis Xanthi, Kokoris Stella I, Dimitriadou Evagelia M, Dimopoulou Maria N, Moschogiannis Maria, Korkolopoulou Penelope, Kyrtsonis Marie-Christine, Siakantaris Marina P, Papadaki Theodora, Tsaftaridis Panayiotis, Plata Eleni, Papadaki Helen E, Vassilakopoulos Theodoros P

Сравнительное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Treatment of splenic marginal zone lymphoma (SMZL) patients is not standardized. Recent data suggest that rituximab is highly effective and could be considered as initial therapy.

AIM: To assess the efficacy of rituximab monotherapy in a large series of patients with SMZL and compare these results with splenectomy results.

METHODS

The studied population included 85 patients. Fifty-eight received rituximab at a dose of 375 mg/m2 per week for 6 weeks as induction followed by maintenance at the same dose every 2 months for 1-2 years, whereas 27 patients were treated using splenectomy only.

RESULTS

The overall response rate to rituximab 2 months after the end of induction was 95% (complete response [CR], 45%; unconfirmed CR, 26%; partial response, 24%). The median times to hematologic and clinical response were 2 weeks and 3 weeks, respectively. Forty-three of 55 patients already completed the maintenance phase: 28 sustained their initial response, 14 improved their response, and one progressed. Eighty-five percent of splenectomized patients responded, and two were treated with rituximab as consolidation after splenectomy and achieved a CR. The 5-year overall and progression-free survival (PFS) rates for rituximab-treated and splenectomized patients were 92% and 77% (p = .09) and 73% and 58% (p = .06), respectively. Furthermore, maintenance therapy with rituximab resulted in a longer duration of response (at 5 years, PFS was 84% for patients receiving maintenance and 36% for patients without maintenance, p <.0001).

CONCLUSIONS

Rituximab is a very effective and well-tolerated therapy and may be substituted for splenectomy as the first-line treatment of choice for patients with SMZL.

Для цитирования: Kalpadakis Christina, Pangalis Gerassimos A, Angelopoulou Maria K, Sachanas Sotirios, Kontopidou Flora N, Yiakoumis Xanthi, Kokoris Stella I, Dimitriadou Evagelia M, Dimopoulou Maria N, Moschogiannis Maria, Korkolopoulou Penelope, Kyrtsonis Marie-Christine, Siakantaris Marina P, Papadaki Theodora, Tsaftaridis Panayiotis, Plata Eleni, Papadaki Helen E, Vassilakopoulos Theodoros P. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.. The oncologist. 2013. DOI: 10.1634/theoncologist.2012-0251.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.